Biography
She is a recent recipient of the American Society of Clinical Oncology (ASCO)/Conquer Cancer 2020 Bonadonna Breast Cancer Research Grant. This grant supports her work as the co-investigator of a clinical trial evaluating the ctDNA status changes during adjuvant treatment of patients with early-stage triple-negative breast cancer who do not respond completely to neoadjuvant chemotherapy.
Dr. Gupta was a member of the combined bachelors/MD program at the University of California – San Diego. She graduated summa cum laude and was inducted into the Gold Humanism in Medicine Honor Society. She completed internship and residency in Internal Medicine at Stanford, during which time she was a recipient of the Julian Wolfsohn Award for clinical achievements in Internal Medicine and was inducted into the Alpha Omega Alpha Honor Medical Society. She then served as a Chief Resident and Clinical Instructor in Internal Medicine. Subsequently, she stayed on at Stanford for fellowship training in Hematology and Medical Oncology.
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Medical Oncology (2021)
- Board Certification: American Board of Internal Medicine, Hematology (2021)
- Fellowship: Stanford University Division of Oncology (2021) CA
- Medical Education: University of California San Diego School of Medicine (2014) CA
- Residency: Stanford University Internal Medicine Residency (2018) CA
- Board Certification: American Board of Internal Medicine, Internal Medicine (2017)
Publications
-
Considering the vascular hypothesis for the pathogenesis of small intestinal atresia: A case control study of genetic factors
Gupta, T., Yang, W., Iovannisci, D. M., Carmichael, S. L., Stevenson, D. K., Shaw, G. M., & Lammer, E. J. (2013). Considering the vascular hypothesis for the pathogenesis of small intestinal atresia: A case control study of genetic factors. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 161A(4), 702–10. -
Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.
Caswell-Jin, J. L., Gupta, T., Hall, E., Petrovchich, I. M., Mills, M. A., Kingham, K. E., … Kurian, A. W. (2017). Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genetics in Medicine : Official Journal of the American College of Medical Genetics. -
Pathogenic variants in less familiar cancer susceptibility genes: what happens after genetic testing?
Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., … Kurian, A. W. (2018). Pathogenic variants in less familiar cancer susceptibility genes: what happens after genetic testing? JCO Precision Oncology. -
Pathogenic germline mutations in emerging cancer genes: What happens after panel testing?
Hall, E. T., Parikh, D. A., Gupta, T., Caswell, J. L., Mills, M., Kingham, K., … Kurian, A. W. (2017). Pathogenic germline mutations in emerging cancer genes: What happens after panel testing? JOURNAL OF CLINICAL ONCOLOGY, 35. -
Incident comorbidities in a diverse cohort of women treated for early-stage, hormone receptor-positive breast cancer
Gupta, T., Purington, N., Liu, M., Han, S., Sledge, G., Schapira, L., & Kurian, A. (2021). Incident comorbidities in a diverse cohort of women treated for early-stage, hormone receptor-positive breast cancer. CANCER RESEARCH, 81(4). -
Online Communities as Sources of Peer Support for People Living With Cancer: A Commentary
Gupta, T., & Schapira, L. (2018). Online Communities as Sources of Peer Support for People Living With Cancer: A Commentary. JOURNAL OF ONCOLOGY PRACTICE, 14(12), 725-+. -
Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?
Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., … Kurian, A. W. (2018). Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing? JCO Precision Oncology, 2, 1–10. -
Neoadjuvant Therapy in Breast Cancer: Histologic Changes and Clinical Implications.
Troxell, M. L., & Gupta, T. (2022). Neoadjuvant Therapy in Breast Cancer: Histologic Changes and Clinical Implications. Surgical Pathology Clinics, 15(1), 57–75. -
Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
Gupta, T., Purington, N., Liu, M., Han, S., Sledge, G., Schapira, L., & Kurian, A. W. (2022). Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer. Breast Cancer Research and Treatment. -
Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta, T., Vinayak, S., & Telli, M. (2022). Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Breast Cancer Research and Treatment.
Practice Locations
Breast Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CABreast Cancer Program in Palo Alto
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Breast Cancer Program in San Jose San Jose, CA
San Jose, CABreast Cancer Program in San Jose
2589 Samaritan Drive
San Jose , CA 95124
Make An Appointment More Clinic Information » Getting Here »Stanford Women's Cancer Center Palo Alto, CA
Palo Alto, CAStanford Women's Cancer Center
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Cancer Center in South Bay San Jose, CA
San Jose, CACancer Center in South Bay
2589 Samaritan Drive
San Jose , CA 95124
Make An Appointment More Clinic Information » Getting Here »Medical Oncology Program in South Bay San Jose, CA
San Jose, CAMedical Oncology Program in South Bay
2589 Samaritan Drive
San Jose , CA 95124
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(103 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records